skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

 

The European Medicines Agency’s pharmacovigilance committee, the PRAC, is due to adopt a recommendation this week on the safety of Gedeon Richter’s uterine fibroid treatmentEsmya(ulipristal acetate). The drug has been the subject of reports of serious liver injury in women taking it.

The PRAC is carrying out a review of the benefit-risk balance of Esmya following a referral under Article 20 of Regulation (EC) No 726/2004, which concerns safety or manufacturing issues with pharmaceutical products. The committee's May meeting, which has been taking place this week in London, ends today. The PRAC is expected to make its final recommendations – to the EMA’s drug evaluation committee, the CHMP – following the meeting. If it does so, these will be forwarded to the European Commission for a legally binding decision. 

In February, as part of the review, the PRAC recommended that women taking Esmya should undergo liver function tests at least once a month, and that if the test results were abnormal (liver enzyme levels more than twice the upper limit of normal) treatment should be stopped, with liver tests repeated two to four weeks later. (Also see "Richter’s Uterine Fibroid Drug Esmya Hit By Liver Safety Concerns In EU" - Pink Sheet, 22 Feb, 2018.)

The temporary safety measures were introduced after a further report of hepatic failure requiring liver transplant with Esmya was received. They included advice that no new patients should be started on Esmya, and that those who had completed a course of treatment should not start another one pending the outcome of the review.

Gedeon Richter said at the time that it expected sales of Esmya to fall by at least 50% as a result of the restrictions, although it insisted that there was no evidence so far of a causal link between Esmya and the liver problems in question. It added that the most likely outcome of the review would be changes to the product information and the introduction of liver tests. (Also see "Richter Expects Esmya Sales To Drop 50% Following EU Restrictions Over Liver Concerns " - Scrip, 23 Feb, 2018.).

Gedeon Richter partner Allergan is seeking approval of Esmya in the US. The EMA review into liver damage prompted the Food and Drug Administration to push back the date by which a decision was due on new drug application by three months to August. (Also see "Keeping Track: Delay (For Celgene), Delay (For Allergan), Goose! (Approval For Lilly)" - Pink Sheet, 4 Mar, 2018.)

 EMA'S REVIEW OF ESMYA

The European Medicines Agency’s pharmacovigilance committee, the PRAC, is due to adopt a recommendation this week on the safety of Gedeon Richter’s uterine fibroid treatment Esmya (ulipristal acetate). The drug has been the subject of reports of serious liver injury in women taking it.

The PRAC is carrying out a review of the benefit-risk balance of Esmya following a referral under Article 20 of Regulation (EC) No 726/2004, which concerns safety or manufacturing issues with pharmaceutical products. The committee's May meeting, which has been taking place this week in London, ends today. The PRAC is expected to make its final recommendations – to the EMA’s drug evaluation committee, the CHMP – following the meeting. If it does so, these will be forwarded to the European Commission for a legally binding decision. 

In February, as part of the review, the PRAC recommended that women taking Esmya should undergo liver function tests at least once a month, and that if the test results were abnormal (liver enzyme levels more than twice the upper limit of normal) treatment should be stopped, with liver tests repeated two to four weeks later. (Also see "Richter’s Uterine Fibroid Drug Esmya Hit By Liver Safety Concerns In EU" - Pink Sheet, 22 Feb, 2018.)

The temporary safety measures were introduced after a further report of hepatic failure requiring liver transplant with Esmya was received. They included advice that no new patients should be started on Esmya, and that those who had completed a course of treatment should not start another one pending the outcome of the review.

Gedeon Richter said at the time that it expected sales of Esmya to fall by at least 50% as a result of the restrictions, although it insisted that there was no evidence so far of a causal link between Esmya and the liver problems in question. It added that the most likely outcome of the review would be changes to the product information and the introduction of liver tests. (Also see "Richter Expects Esmya Sales To Drop 50% Following EU Restrictions Over Liver Concerns " - Scrip, 23 Feb, 2018.).

Gedeon Richter partner Allergan is seeking approval of Esmya in the US. The EMA review into liver damage prompted the Food and Drug Administration to push back the date by which a decision was due on new drug application by three months to August. (Also see "Keeping Track: Delay (For Celgene), Delay (For Allergan), Goose! (Approval For Lilly)" - Pink Sheet, 4 Mar, 2018.)

おすすめのニュース&レポート

;

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問合せの際は下記メールアドレスまたは各営業スタッフまでご連絡下さいますようご協力をお願い申し上げます。

インフォーマインテリジェンス合同会社
ファーマインテリジェンス
inquiry.jp@informa.com

*Omdia(ICT産業の情報)に関するお問い合わせはこちら
Contact_OmdiaJapan@omdia.com


オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。